Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediniceWAR:ICE +0.50%25 14-Day RSI is 58.09 as of Aug. 08, 2026. GuruFocus rates WAR:ICE with a GF Score™ of 25/100 and a GF Value™ of zł0.99 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 866 Medical Devices & Instruments companies, Medinice ranks worse than 78.06% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-08-08), Medinice's 14-Day RSI is 58.09.
The industry rank for Medinice's 14-Day RSI or its related term are showing as below:
WAR:ICE's 14-Day RSI is ranked worse than 78.06% of 866
companies
in the Medical Devices & Instruments industry
Industry Median: 49.78
vs WAR:ICE: 58.09
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Medinice 14-Day RSI Related Terms
WAR:ICE vs ABT, SYK, MDT: 14-Day RSI Comparison
For the Medical Devices subindustry, Medinice's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medinice 14-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medinice's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Medinice's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medinice (WAR:ICE) has a 14-Day RSI of 58.09 as of Aug. 08, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Medinice and its competitors. According to the industry distribution chart, Medinice ranks #676 out of 866 companies in the Medical Devices & Instruments industry, placing it in the top 78.1%.
Is Medinice's 14-Day RSI too high?
Medinice's current 14-Day RSI is 58.09. The Medical Devices & Instruments industry median 14-Day RSI is 49.78. Medinice's value of 58.09 is 16.7% above this industry median. Based on the distribution chart, Medinice ranks #676 out of 866 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Medinice has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medinice's 14-Day RSI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medinice ranks #676 out of 866 companies for 14-Day RSI. This places Medinice in the lower half of its industry. The industry median 14-Day RSI is 49.78. Medinice's value of 58.09 is 16.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Devices & Instruments company?
The median 14-Day RSI among Medical Devices & Instruments companies is 49.78, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medinice's current 14-Day RSI of 58.09 is 16.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Medinice and its competitors. For the Medical Devices & Instruments industry, the median 14-Day RSI is 49.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medinice's current 14-Day RSI is 58.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medinice stock overvalued right now?
Based on GuruFocus' analysis, Medinice (WAR:ICE) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.99, compared to a current price of zł80.80 — trading 8061.6% above its estimated fair value. The current 14-Day RSI is 58.09 and 16.7% above the Medical Devices & Instruments industry median of 49.78. Medinice's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Medinice (WAR:ICE), the current 14-Day RSI is 58.09 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medinice (WAR:ICE) Overvalued in 2026?
Based on GuruFocus' analysis, Medinice stock appears to be overvalued.
The current stock price of zł80.80 is trading 8061.6% above its estimated GF Value™ of zł0.99.
GuruFocus considers Medinice to be Significantly Overvalued.
Key valuation signals for WAR:ICE:
14-Day RSI: 58.09
GF Value™: zł0.99 vs. price of zł80.80 (8061.6% above fair value)
Industry Position: 16.7% above the Medical Devices & Instruments median (#676 of 866)
No single metric tells the full story. See the WAR:ICE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medinice SA is a Polish company operating in the MedTech industry. The company is engaged in creating, developing and commercializing solutions in the field of medicine, in particular, cardiology and cardio surgery. Its portfolio includes close around 12 projects including CathAIO, an electrode with universal diagnostic, electrophysiological, haemodinamic and biohemic functions and can be used for RF ablation; cryoapplicator, for minimally invasive cardiosurgical cryoablation; Med-iConsole allows to reduce the need to use multiple computer devices during electrophysiological treatment; Minimax and Pacepress.
25GF Score
Get the complete analysis for WAR:ICE
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:ICE has been successfully added to your 
